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Background: Thyroid dysfunction is a well-known adverse effect of first-generation tyrosine kinase inhibitors
(TKIs), like sunitinib. The aim of this study was to investigate the effect of second-generation TKIs on thyroid
function.
Methods: We retrospectively assessed the effect of the first-generation TKI imatinib and the second-generation
TKI nilotinib and dasatinib on thyroid function tests in 73 Philadelphia chromosome-positive (Ph-positive)
chronic myeloid leukemia patients.
Results: Overall, 33 of 73 (45%) had one or more thyroid function test abnormalities during follow-up. Hy-
pothyroidism or hyperthyroidism were found in 18 of 73 (25%) and 21 of 73 (29%) cases after a median of 6 and
22 weeks, respectively. In most patients (29 of 39, 74%) thyroid dysfunction was transient without clinical
symptoms. Therapy of hypo-/hyperthyroidism was required in three patients. Thyroid dysfunction never re-
sulted in the discontinuation of TKI therapy. Under treatment with imatinib, nilotinib, and dasatinib, thyroid
abnormalities were detected in 25%, 55%, and 70%, respectively. Four of 55 patients (7%) treated with nilotinib
had evidence for an autoimmune thyroiditis (antibody positive in 3 of 4 patients) with an episode of hyper-
thyroidism preceding hypothyroidism.
Conclusions: Thyroid dysfunction is a common adverse event with second-generation TKI therapy in patients
with Ph-positive chronic myeloid leukemia. Although the mechanism is still unclear, the high frequency of
thyroid abnormalities, including autoimmune thyroiditis, warrants regular and long-term monitoring of thyroid
function in these patients.
Introduction
Thyroid dysfunction, mostly hypothyroidism, is a well-recognized side effect of treatment with tyrosine kinase
inhibitors (TKIs) (1–3). Its incidence ranged from 53% to 85%
in retrospective and from 36% to 71% in prospective studies.
Sunitinib malate, a multitargeted small-molecule TKI, has
been reported to cause hypothyroidism in patients with
metastatic renal cell carcinoma and gastrointestinal stromal
tumors (4–6). Possible mechanisms include the induction of a
destructive thyroiditis (4,7,8), the inhibition of peroxidase
activity (9), the blocking of iodine uptake (10), irreversible
thyroid destruction (11), or capillary dysfunction (9,12), tar-
geting vascular endothelial growth factor (VEGF) receptors
via its antiangiogenic activity. Due to the high incidence of
hypothyroidism in patients treated with sunitinib, a routine
control algorithm has recently been proposed (13). However,
hypothyroidism does not require the interruption of treat-
ment per se since replacement with levothyroxine seems to be
effective (5,6). In addition, thyroid dysfunction has also been
described with sorafenib (14) and motesanib (15), though at
much lower rates.
Several TKIs specifically target the oncogenic activity of the
breakpoint cluster region (BCR)-agelson murine leukemia
viral oncogene homolog (ABL) protein in patients with Phi-
ladelphia chromosome-positive (Ph-positive) chronic mye-
loid leukemia (CML) (16). The first-generation TKI imatinib
mesylate is the standard of care and leads to durable remis-
sions in the majority of patients in chronic phase (CP)
CML (17). However, long-term results from the IRIS study
(International Randomized Study of Interferon vs STI571)
show that >30% of patients with newly diagnosed CML-CP
discontinue imatinib within 6 years (18). For patients with
imatinib-resistance or -intolerance, two second-generation
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TKIs, nilotinib and dasatinib, are currently approved (19,20).
Whereas nilotinib was rationally designed on the structural
basis of imatinib for greater potency and specificity with
respect to BCR-ABL inhibition (21,22), dasatinib is a dual
sarcoma (SRC)/ABL inhibitor with less stringent conforma-
tional requirements and a wider spectrum of targets (23).
Clinically, both show considerable activity after imatinib
failure (24,25) and in previously untreated patients (26,27).
It is unclear at present whether second-generation TKIs
with increased specificity share the same adverse effects as
first-generation TKIs like sunitinib and imatinib. Data on the
incidence of thyroid dysfunction in patients treated with
second-generation TKIs are not available. The current study
therefore retrospectively investigated the incidence of thyroid
dysfunction during therapy with the second-generation TKIs,
nilotinib and dasatinib, in patients with CML-CP.
Materials and Methods
Patients
Between May 2005 and July 2009, 71 patients with Ph-
positive CML in CP (n¼ 67), accelerated phase (n¼ 3), and
hypereosinophilic syndrome (n¼ 1) were treated in our
center with imatinib, nilotinib, and/or dasatinib as first-line,
second-line, or, in rare instances, as third-line treatment.
Most patients were treated within clinical trials (Clinical-
trials.gov: NCT00471497, NCT00109707, and NCT00905593).
Patients gave their informed written consent to participate in
a clinical trial or to have their data analyzed retrospectively.
All procedures were followed in accordance with the Hel-
sinki Declaration and were approved by the local ethics
committee. Patients received imatinib 400mg qd, nilotinib
400mg bid, and/or dasatinib 100mg qd with dose reduc-
tions for toxicity and, in the case of imatinib, dose escalation
for incomplete response as necessary. Patients were followed
regularly every 3 to 6 months. Determination of disease
stage and response criteria were done according to standard
criteria (28).
Evaluation of thyroid function
Thyroid function tests (TFTs) at baseline and during follow-
up included serum thyroid-stimulating hormone (TSH), free
triiodotyronine (fT3), and free thyroxine (fT4). In four cases
antibodies against thyroid peroxidase (TPOAb), thyroglobulin
(TgAb), and the TSH receptor (TRAb) were determined due to
the development of hypothyroidism that was preceded by an
episode of hyperthyroidism during follow-up (see below).
Serum TSH, fT3, and fT4 were measured by an electro-
chemiluminescent immunoassay (ECLIA; Roche, Grenzach-
Wyhlen, Germany); TPOAb and TgAb by an luminescence
immunoassay with time-resolved amplified cryptate emission
(TRACE) technology (Brahms, Hennigsdorf, Germany); and
TRAb by a electrochemiluminescent receptor assay (Elecsys;
Roche). Serum samples were collected, handled, and ana-
lyzed according to internal standard operating procedures.
Laboratory reference ranges are 0.27–4.20mU/L for TSH,
2.6–5.1 ng/L for fT3, and 0.9–1.9 ng/dL for fT4. Upper limits
for antibody positivity were>60 kU/L for TgAb and TPOAb,
and >1.8 IE/L for TRAb. Thyroid ultrasonography and
Color Doppler ultrasonography were performed in four pa-
tients (see below).
Definition of hypothyroidism and hyperthyroidism
The biochemical diagnosis of subclinical hypothyroidism
and hyperthyroidism was defined in accordance with the
guidelines of the American Thyroid Association, the Ameri-
can Association of Clinical Endocrinologists and the Endo-
crine Society (29,30). Subclinical hypothyroidism is defined as
a serum TSH concentration above the upper limit of normal
(4.20mU/L)with fT4 concentrationwithin its reference range,
and subclinical hyperthyroidism is defined as a serum TSH
concentration below the lower limit of normal (0.27mU/L)
with fT4 and fT3 concentration within their reference ranges.
Hyperthyroidism is defined as a serum TSH concentration
below 0.1mIU/L and serum fT4 or fT3 concentrations above
the normal reference range, and hypothyroidism is defined as
a low serum fT4 concentration with elevated serum TSH
concentration. Thyroid hormone replacement therapy and
treatment with antithyroid medication was initiated at the
discretion of the treating physician depending upon the
clinical presentation. Patients with biochemical subclinical
hypothyroidism or hypothyroidism and symptoms compati-
ble with hypothyroidism (e.g., fatigue, cold intolerance, con-
stipation, or weight gain) received thyroid hormone
replacement therapy with levothyroxine. All patients with
hyperthyroidism and symptoms compatible with hyperthy-
roidism (e.g., anxiety, weakness, tremor, palpitations, heat
intolerance, increased perspiration, and weight loss, despite a
normal or increased appetite and diarrhea) were treated with
antithyroid medication.
Results
Patient characteristics
Overall, 64 of 71 patients had TFTs available (Table 1). For
the purpose of this study, patients were allocated to three
groups with 8, 55, and 10 patients being treatedwith imatinib,
nilotinib, and dasatinib, respectively. Since some patients se-
quentially received different TKIs, the sum of these three
groups is higher than the number of actual patients. Median
age was 57 years (range 25–85) and median follow-up 16
months (range 1–51). Eleven patients had a previous history
of thyroid dysfunction with (partial) thyroidectomy in four
cases, hypothyroidism in six cases, and goiter in one case.
Nine patients were receiving levothyroxine therapy at study
entry (eight for hypothyroidism and one for a goiter), of
whom one was hyperthyroid, one had subclinical hyperthy-
roidism, and the remainder normal thyroid function. Twelve
patients received medications known to potentially interfere
with thyroid function (11 salicylates, 1 glucocorticoids, and 1
amiodarone), of whom 1 had subclinical hyperthyroidism
and 1 subclinical hypothyroidism. None had received radio-
iodine therapy or external neck irradiation. Median disease
duration of CML was 29 months (range 0–218). Before
imatinib, nilotinib, and dasatinib, 0/8 (0%), 18/55 (33%), and
3/10 (30%) had received interferon, respectively.
TFTs during TKI therapy
At baseline, median TSHwas 1.33mU/L (range 0.01–7.05).
Ten patients had abnormal baseline TFTs: five had elevated
TSH concentration, all with normal fT4 and fT3 values with-
out treatment, and five had suppressed TSH concentrations,
with four patients having normal fT4 and fT3 values without
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treatment and one patient having increased fT4 under le-
vothyroxine substitution therapy. Sixty-three of 73 patients
(86%) were euthyroid at baseline (Table 1). During the study
period, 40 of 73 patients (55%) had normal thyroid function,
whereas 33 of 73 patients (45%) had one or more TFT abnor-
malities (Table 2). Eighteen (25%) and 21 patients (29%) of 73
patients had hypothyroidism and hyperthyroidism, respec-
tively. Mean TFTs were similar when analyzed at 3, 6, and 12
months (Fig. 1).
Time course and clinical management
of abnormal thyroid function
Most cases of hypothyroidism (11 of 17, 65%) or hyper-
thyroidism (13 of 21, 62%)were transient with 6 and 4 patients
developing persistent hypothyroidism or hyperthyroidism,
respectively (Table 3). Hyperthyroidism was detected rela-
tively early after a median of 6 weeks (range 1–70), whereas
hypothyroidism occurred after a median of 22 weeks (range
1–135). Clinically, there were only three instances of signs and
symptoms possibly related to hyperthyroidism. Two cases of
diarrhea, and one case of atrial fibrillation. The latter had had a
history of paroxysmal atrial fibrillation for 20 years and had a
single brief self-limiting episode 2months after the initiation of
treatment. None received antithyroid treatment. One patient
on nilotinib was briefly being treatedwithmethimazole before
developing transient hypothyroidism (see below), and two
hypothyroid patients started levothyroxine. One of these
two patients was under amiodarone with slightly elevated
TSH at baseline and levothyroxine was initiated when taking
dasatinib. Of the 10 patients with a previous history of thyroid
dysfunction receiving thyroid medication, only one had his
Table 1. Patient Characteristics
Total Imatinib Nilotinib Dasatinib
n 73 8 55 10
Male 36 5 27 4
Female 37 3 28 6
Median age (range) 57 (25–85) 45.5 (28–70) 61 (25–85) 57.5 (26–73)
Follow-up (days, range) 500 (20–1547) 201 (112–594) 595 (104–1547) 412 (20–687)
Disease/indication
CML-CP 66 (90) 8 51 7
CML-AP 6 (8) 0 3 3
HES 1 (1) 0 1 0
Median disease duration (months, range) 29 (0–218) 1 (0–1) 32 (0–180) 56.5 (0–218)
Previous treatment
HU (%) 62 (85) 5 (63) 48 (87) 9 (90)
IFN (%) 21 (29) 0 18 (33) 3 (30)
Other (%) 16 (22) 0 13 (24) 3 (30)
SCT (%) 1 (1) 0 1 (2) 0
Imatinib (%) 49 (67) NA 40 (73) 9 (90)
Nilotinib (%) 7 (10) 0 NA 7 (70)
Dasatinib (%) 0 0 0 NA
Thyroid history before TKIsa 11 (15) 1 (13) 7 (13) 3 (30)
Thyroid medication before TKIsb 9 (12) 1 (13) 6 (11) 2 (20)
Baseline TFT
TSH (median, range) 1.33 (0.01–7.05) 2.36 (1.24–4.28) 1.1 (0.01–7.05) 1.39 (0.7–4.46)
Normal thyroid function 63 (86) 7 (88) 48 (87) 8 (80)
Hypothyroidism 5 (7) 1 (13) 2 (4) 2 (20)
Hyperthyroidism 5 (7) 0 5 (9) 0
aPartial thyroidectomy (n¼ 4), hypothyroidism (n¼ 6), and goiter (n¼ 1).
bAll levothyroxine.
AP, accelerated phase; CML, chronic myeloid leukemia; CP, chronic phase; HES, hypereosinophilic syndrome; HU, hydroxyurea; IFN,
interferon alpha; NA, not applicable; SCT, stem cell transplantation; TFT, thyroid function test; TKI, tyrosine kinase inhibitor; TSH, thyroid-
stimulating hormone.
Table 2. Thyroid Function Test Abnormalities During Tyrosine Kinase Inhibitor Therapy
Total Imatinib Nilotinib Dasatinib
Normal thyroid function (%) 40 (55) 6 (75) 30 (55) 4 (40)
Hypothyroidism (%) 18 (25) 1 (13) 12 (22) 5 (50)
Subclinical (%) 11 (15) 1 (13) 6 (11) 4 (40)
Clinical (%) 7 (10) 0 6 (11) 1 (10)
Hyperthyroidism (%) 21 (29) 1 (13) 18 (33) 2 (20)
Subclinical (%) 13 (18) 1 (13) 10 (18) 2 (20)
Clinical (%) 8 (11) 0 8 (15) 0
Patients can have more than one abnormality.
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levothyroxine stopped, whereas all others continued their
treatment without any change in thyroid hormone or TSH
concentration during therapy. Among the 21 patientswho had
previously received interferon, 5 had hypothyroidism (2 sub-
clinical and 3 clinical), and 9 had hyperthyroidism (6 sub-
clinical and 3 clinical). Although these abnormalities were
slightly more common as compared to all other patients, this
was not statistically significant.
Drug-induced thyroiditis during TKI therapy
Of 18 patients with hypothyroidism during follow-up, 4,
all being treated with nilotinib, had a preceding episode of
hyperthyroidism (Fig. 2 and Table 3). Hyperthyroidism
occurred after a median 19 weeks (range 44–378), and hypo-
thyroidism after a median of 35 weeks (range 112–420). TgAb
were detected in three of four patients (28, 192.6, and
683.2 kU/L) and TPOAb in one of four (680 kU/L). The fourth
patient had no thyroid autoantibodies when assessed for the
first time >3 years after this episode. All four patients had
sonographic abnormalities, with two patients having hy-
poechoic areas and two having multiple nodules. Clinically,
hypothyroidism resolved spontaneously in three of these
patients, and one patient was started on levothyroxine due to
clinical overt hypothyroidism. However, since follow-up is
short in this patient, a transient state cannot be excluded.
Discussion
Thyroid dysfunction is a well-known adverse effect of
first-generation TKI therapy (1–3). Athyroid patients with
CML (31,32) or metastatic medullary thyroid carcinoma (33)
simultaneously being treated with thyroid hormones and
imatinib seem to need a significant increase of the levothyr-
oxine replacement dose. Increased nondeiodination clearance
through enzyme induction has been proposed as a potential
mechanism (32). However, there was no thyroid dysfunction
in patients with the thyroid in situ (34).
Here, we analyzed thyroid function through serial moni-
toring of TFTs in patients being treated with imatinib, niloti-
nib, and dasatinib. To avoid the potential influence of
comorbidities as well as the influence of CML cells and in-
tensive treatment regimens on thyroid function, only patients
with CML in chronic or early accelerated phase and one pa-
tient with hypereosinophilic syndrome were included in the
present study
Thyroid abnormalities were very common with only about
a third of the population being strictly euthyroid during
follow-up. Both hypothyroidism and hyperthyroidism were
each found in about a quarter of patients. However, these
changes were mostly subclinical and transient and, according
to the American Thyroid Association guidelines (30), rarely
needed any treatment. Due to the transient nature of drug-
induced hypo- or hyperthyroidism, as well as themild clinical
course with lack of symptoms in all but two patients, no
specific treatment was initiated. The therapeutic relevance of
early diagnosis of hypothyroidism or hyperthyroidism is
therefore unclear. Due to the retrospective nature of this
study, more detailed analyses of mechanisms were not pos-
sible. However, 4 of 18 patients (22%) with hypothyroidism
and 4 of 55 patients (7%) being treated with nilotinib had
evidence for an autoimmune thyroiditis, which, however, did
not lead to persistent hypothyroidism. Only one of these four
FIG. 1. (a) TSH, (b) fT4, and (c) fT3 levels during treatment with imatinib (n¼ 8), nilotinib (n¼ 55), and dasatinib (n¼ 10).
Shown are baseline and follow-up values at 3, 6, and 12 months after initiation of the tyrosine kinase inhibitor. fT3, free
triiodotyronine; fT4, free thyroxine; TSH, Thyroid-stimulating hormone.
Table 3. Kinetics of Thyroid Function Test Abnormalities
Total Imatinib Nilotinib Dasatinib
Hypothyroidism (%) 18 (25) 1 (13) 12 (22) 5 (50)
Transient 12 (16) 1 (13) 8 (15) 3 (30)
Persistent 6 (8) 0 4 (7) 2 (20)
Median time to abnormal TSH (weeks, range) 154 (7–944) 7 248 (22–944) 142 (7–370)
Hyperthyroidism (%) 21 (29) 1 (13) 18 (33) 2 (20)
Transient 17 (23) 1 (13) 15 (27) 1 (10)
Persistent 4 (5) 0 3 (5) 1 (10)
Median time to abnormal TSH (weeks, range) 44 (7–488) 480 43 (6–488) 41.5 (19–64)
Hypothyroidism with previous hyperthyroidism 4 (5) 0 4 (7) 0
Hypothyroidism without previous hyperthyroidism 14 (19) 1 (13) 8 (15) 5 (50)
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patients, who did not have autoantibodies, had previously
been treated with interferon arguing against cytokine-in-
duced generation of autoantibodies as a major factor.
In conclusion, we found thyroid dysfunction to be com-
mon in patients with Ph-positive CML under treatment with
imatinib and the second-generation TKIs, nilotinib and da-
satinib. However, these abnormalities rarely implied a
change in clinical management or required treatment, and
never led to discontinuation of the TKI. Due to the inherent
limitations of a retrospective, uncontrolled study and the
sample size of our cohort no direct comparisons between
different drug therapies is possible. Nevertheless, the fre-
quency of thyroid abnormalities and occurrence of cases
with evidence for thyroiditis indicates that these patients
should be monitored regularly. Despite their reported kinase
specificity, TKIs share still elusive off-target effects that fre-
quently result in abnormal TFTs, including autoimmune
thyroiditis. We therefore suggest careful monitoring of TFTs
in second-generation TKI-treated patients.
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